COVID

Edison issues update on abrdn UK Smaller Companies Growth Trust (AUSC): Relative performance getting back on track

Retrieved on: 
Wednesday, March 13, 2024

abrdn UK Smaller Companies Growth Trust’s (AUSC’s) managers, Abby Glennie and Amanda Yeaman, are looking forward to further improvement in the trust’s relative performance, as investors’ focus is now more on company fundamentals rather than macroeconomic developments.

Key Points: 
  • abrdn UK Smaller Companies Growth Trust’s (AUSC’s) managers, Abby Glennie and Amanda Yeaman, are looking forward to further improvement in the trust’s relative performance, as investors’ focus is now more on company fundamentals rather than macroeconomic developments.
  • The managers are continuing to use the Matrix, a proprietary screening tool, to search for companies exhibiting high-quality, growth and positive momentum features.
  • Many portfolio names have positive earnings estimates revisions, which suggests a robust operating environment; this is confirmed in meetings with companies.
  • While AUSC aims to generate capital growth there has been solid progression in its annual dividend, supported by a diverse income stream.

EQS-News: Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

Retrieved on: 
Wednesday, March 13, 2024

Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

Key Points: 
  • Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
    The issuer is solely responsible for the content of this announcement.
  • Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
    Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally.
  • The ongoing Phase II clinical trial in Long COVID seeks to deliver conclusive and reliable results on the drug's effectiveness and safety for patients.
  • With the ongoing Phase II trial focusing on Long COVID, Berlin Cures continues to seek additional investments and partnerships to advance this groundbreaking opportunity.

EQS-News: Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Retrieved on: 
Wednesday, March 13, 2024

“Having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious ACTRIMS Forum is a testament to the strength of the data we have generated,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.

Key Points: 
  • “Having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious ACTRIMS Forum is a testament to the strength of the data we have generated,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • We believe that the data set provides biomarker evidence that vidofludimus calcium’s activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential.
  • Recent third-party data in post COVID patients identified EBV reactivation as a potential cause for fatigue in this patient group.
  • Fox, MD, Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio

Early Pulmonary Fibrosis Detection Holds the Key to Better Health Outcomes for Canadians Living with COVID-19 and Rheumatoid Arthritis

Retrieved on: 
Wednesday, February 28, 2024

Canadians who have had COVID-19, and other chronic diseases, are experiencing Pulmonary Fibrosis (PF) at significantly higher rates than others, seemingly providing a causal link that researchers are investigating.

Key Points: 
  • Research is shedding light on the growing rate of pulmonary fibrosis (PF) being found in people suffering from long-term COVID-19.
  • One study, Post COVID-19 pulmonary fibrosis; a meta-analysis study , found that almost 45% (44.9%) of study participants began suffering from PF after contracting COVID-19.
  • Canadians suffering from long COVID are encouraged to watch for the early signs of pulmonary fibrosis, a disease that is growing in this population.
  • Dr. Janet Pope's webinar includes explanations for both physicians and thousands of people living with connective tissue diseases of what pulmonary fibrosis symptoms to watch for.

One of 2024's Must Read Organizational Leadership Books Is 'Chaos Is a Gift?' by Author Dr. Andrew Campbell

Retrieved on: 
Tuesday, February 27, 2024

Andrew Campbell and Ebben Van Zyl are proud to introduce the audiobook version of their acclaimed book Chaos Is a Gift?

Key Points: 
  • Andrew Campbell and Ebben Van Zyl are proud to introduce the audiobook version of their acclaimed book Chaos Is a Gift?
  • is perfect for organizational leaders who, in times of unpredictability and uncertainty, seek to lead with focus, clarity, and calmness.
  • Developing the capacity to lead oneself in times of organizational chaos and unpredictability is a critical ingredient in solving organizational challenges.
  • His research focuses on global leadership, organizational leadership, international conflict management and terrorism, and leadership forgiveness and reconciliation.

Industry Orgs Applaud Bill to Boost Bars, Restaurants and Venues with Draft Systems

Retrieved on: 
Monday, March 11, 2024

The CHEERS Act would provide a tax deduction for bars, restaurants and entertainment venues with draft beer systems to help revitalize hospitality establishments still struggling years after the pandemic.

Key Points: 
  • The CHEERS Act would provide a tax deduction for bars, restaurants and entertainment venues with draft beer systems to help revitalize hospitality establishments still struggling years after the pandemic.
  • This bipartisan bill will support these local establishments by incentivizing the expansion of tap lines and keg equipment on commercial premises.
  • “The CHEERS Act would boost not only our smaller bars, clubs and entertainment venues but also many of our casinos, hotels and arenas.
  • And we will reduce waste created by using smaller, disposable containers at many restaurants, bars and other venues.

FINAL DEADLINE REMINDER FOR BNTX INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against BioNTech SE (BNTX)

Retrieved on: 
Monday, March 11, 2024

The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

Extendicare Announces 2023 Fourth Quarter and Year End Results

Retrieved on: 
Friday, March 8, 2024

MARKHAM, Ontario, March 07, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and twelve months ended December 31, 2023.

Key Points: 
  • MARKHAM, Ontario, March 07, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and twelve months ended December 31, 2023.
  • Beds under management through Extendicare Assist grew 64.2% to 9,783 from Q4 2022 driven by the Revera and Axium transactions.
  • “Our strong fourth quarter is the result of the strategic initiatives we have undertaken to reposition Extendicare for growth and value creation,” said Dr. Michael Guerriere, President and Chief Executive Officer.
  • In November 2023, Axium Extendicare LTC II LP (“Axium JV II”) acquired a new 320-bed LTC redevelopment project in Ottawa from Revera.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX)

Retrieved on: 
Thursday, March 7, 2024

On this news, BioNTech’s stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.

Key Points: 
  • On this news, BioNTech’s stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.
  • On this news, BioNTech’s stock price fell $4.60, or 3.6%, to close at $123.60 per share on March 27, 2023.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.